Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cornelia Tillack-Schreiber

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Inflammatory Bowel Diseases|October 12, 2011
Malignant melanoma during ustekinumab therapy of Crohn's diseaseLaura M Ehmann, Cornelia Tillack-Schreiber, Stephan Brand, et al.
MMW Fortschritte Der Medizin|October 31, 2025
[Chronic inflammatory bowel diseases in general practice]Thomas Ochsenkühn, Cornelia Tillack-Schreiber, Daniel Szokodi, et al.
Crohn'S & Colitis 360|February 13, 2023
Early Start of Infliximab in Crohn's Disease Increases Rates of Endoscopic Remission and Decreases Stenosis Formation: Experiences From a Single Center CohortFabian Schnitzler, Theresia Seitz, Cornelia Tillack-Schreiber, et al.
Alimentary Pharmacology & Therapeutics|August 28, 2020
Letter: immunotherapy in IBD patients in a SARS-CoV-2 endemic areaConstanze H Waggershauser, Cornelia Tillack-Schreiber, Christine Berchtold-Benchieb, et al.
Plos One|January 18, 2024
Safety of perioperative treatment with biologics in patients with inflammatory bowel disease undergoing bowel surgery: Experience from a large urban centerFabian Schnitzler, Cornelia Tillack-Schreiber, Daniel Szokodi, et al.
Canadian Journal of Gastroenterology & Hepatology|September 5, 2022
Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD PatientsConstanze Heike Waggershauser, Cornelia Tillack-Schreiber, Paul Weyh, et al.
Inflammatory Bowel Diseases|August 12, 2015
Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype StatusJohannes Stallhofer, Matthias Friedrich, Astrid Konrad-Zerna, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Inflammatory Bowel Diseases|October 12, 2011
Malignant melanoma during ustekinumab therapy of Crohn's diseaseLaura M Ehmann, Cornelia Tillack-Schreiber, Stephan Brand, et al.
MMW Fortschritte Der Medizin|October 31, 2025
[Chronic inflammatory bowel diseases in general practice]Thomas Ochsenkühn, Cornelia Tillack-Schreiber, Daniel Szokodi, et al.
Crohn'S & Colitis 360|February 13, 2023
Early Start of Infliximab in Crohn's Disease Increases Rates of Endoscopic Remission and Decreases Stenosis Formation: Experiences From a Single Center CohortFabian Schnitzler, Theresia Seitz, Cornelia Tillack-Schreiber, et al.
Alimentary Pharmacology & Therapeutics|August 28, 2020
Letter: immunotherapy in IBD patients in a SARS-CoV-2 endemic areaConstanze H Waggershauser, Cornelia Tillack-Schreiber, Christine Berchtold-Benchieb, et al.
Plos One|January 18, 2024
Safety of perioperative treatment with biologics in patients with inflammatory bowel disease undergoing bowel surgery: Experience from a large urban centerFabian Schnitzler, Cornelia Tillack-Schreiber, Daniel Szokodi, et al.
Canadian Journal of Gastroenterology & Hepatology|September 5, 2022
Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD PatientsConstanze Heike Waggershauser, Cornelia Tillack-Schreiber, Paul Weyh, et al.
Inflammatory Bowel Diseases|August 12, 2015
Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype StatusJohannes Stallhofer, Matthias Friedrich, Astrid Konrad-Zerna, et al.
Pageof 1